(Cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles

Patent metadata

Field	Value
Publication number	US-10112934-B2
Application number	US-201715491035-A
Country	US
Kind code	B2
Filing date	Apr 19, 2017
Priority date	May 17, 2013
Publication date	Oct 30, 2018
Grant date	Oct 30, 2018

Abstract

This invention relates to novel (Cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles and their use as CB2 cannabinoid receptor agonists, pharmaceutical compositions containing the same, and their use for the treatment of CB2 receptor mediated disorders or conditions.

First claim

The invention claimed is:

1. A method of treating pain selected from the group consisting of acute pain, visceral pain, and neuropathic pain, comprising administering to a human being an effective amount of a compound selected from the group consisting of

and a pharmaceutically acceptable salt thereof, to treat the pain.

2. The method of claim 1 , wherein the compound is

3. The method of claim 1 , wherein the pain is acute pain.

4. The method of claim 2 , wherein the pain is acute pain.

5. The method of claim 3 , wherein the acute pain is trigeminal neuralgia.

6. The method of claim 4 , wherein the acute pain is trigeminal neuralgia.

7. The method of claim 1 , wherein the pain is visceral pain.

8. The method of claim 2 , wherein the pain is visceral pain.

9. The method of claim 1 , wherein the pain is neuropathic pain.

10. The method of claim 2 , wherein the pain is neuropathic pain.

11. The method of claim 9 , wherein the neuropathic pain is post-herpetic neuralgia.

12. The method of claim 10 , wherein the neuropathic pain is post-herpetic neuralgia.

13. The method of claim 9 , wherein the neuropathic pain is due to multiple sclerosis.

14. The method of claim 10 , wherein the neuropathic pain is due to multiple sclerosis.

15. The method of claim 9 , wherein the neuropathic pain is due to chemotherapy caused nerve injury.

16. The method of claim 10 , wherein the neuropathic pain is due to chemotherapy caused nerve injury.

17. The method of claim 9 , wherein the neuropathic pain is due to central nervous system injury.

18. The method of claim 10 , wherein the neuropathic pain is due to central nervous system injury.

19. The method of claim 1 , wherein the compound is administered in the form of a tablet, pill, or capsule.

20. The method of claim 3 , wherein the compound is administered in the form of a tablet, pill, or capsule.

21. The method of claim 9 , wherein the compound is administered in the form of a tablet, pill, or capsule.

22. A method of treating complex regional pain syndrome type I, comprising administering to a human being an effective amount of a compound selected from the group consisting of

and a pharmaceutically acceptable salt thereof, to treat the complex regional pain syndrome type I.

23. The method of claim 22 , wherein the compound is

24. A method of treating pain due to osteoarthritis, comprising administering to a human being an effective amount of a compound selected from the group consisting of

and a pharmaceutically acceptable salt thereof, to treat the pain due to osteoarthritis.

25. The method of claim 24 , wherein the compound is

Assignees

• Centrexion Therapeutics Corp

Inventors

• Riether Doris
• Binder Florian Paul Christian
• Doods Henri
• Mueller Stephan Georg
• Nicholson Janet Rachel
• Sauer Achim

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P39/00

  General protective or antinoxious agents · CPC title

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title

• A61P25/04

  Centrally acting analgesics, e.g. opioids · CPC title

• A61P25/02

  for peripheral neuropathies · CPC title